Experience
Roger Franklin (born 1979) holds a Ph.D. in oncology from the University of Cambridge. Roger has more than 15 years of experience from the life science industry, including positions as senior analyst in pharmaceuticals and biotech at a London-based investment bank and as investment manager at a large London-based life science venture capital fund. Roger currently serves as Partner at Hadean Ventures, a Stockholm/Oslo-based European life science venture fund.

Other assignments
Board Director of Abliva AB (Sweden) and TargED Biopharmaceuticals BV (Netherlands)
Board Observer at Pipeline Therapeutics Inc, San Diego (USA), Step Pharma SAS (France), Emergence Therapeutics AG (Germany), and Cardior Pharmaceuticals GmbH (Germany)

Experience
Charlotte Edenius (born 1958), M.D, Ph.D., is one of the co-founders of Gesynta Pharma. Charlotte has more than 25 years of experience from positions within the life science industry with experience from all phases of drug development as well as business development including successful partnering and licensing. Her experience spans from AstraZeneca to biotech companies including senior management positions as EVP R&D, Medivir AB, SVP Research, Orexo AB, and CSO, Biolipox AB. Charlotte has also served in non-executive board positions in several private and public pharma companies, including Karolinska Development AB.

Other assignments
Board Director of Kancera AB (publ)
Chairman of the Board and CEO of Allmora Life Science AB

Experience
Nikolaj Sørensen (born 1972), M.Sc. in International Business from Copenhagen Business School. Nikolaj has more than 20 years of experience from the life science and pharmaceutical industry in Sweden and abroad, including senior management positions at Pfizer and as management consultant at the Boston Consulting Group (BCG). Nikolaj currently serves as President and CEO of Orexo AB.

Other assignments
Board Director of Bioservo Technologies AB and Moberg Pharma AB

Experience
Gunnar Olsson (born 1953), M.D., Ph.D., is a specialist in cardiology and internal medicine. From 1998 to 2010, Gunnar held a position as adjunct professor at the Department of Medicine at Karolinska Institutet. He holds an honorary doctorate in medicine at Gothenburg University. Gunnar has more than 30 years of experience from positions within the life science industry. He has served as Vice President & Head of Cardiovascular & Gastrointestinal Therapy Areas at Global R&D at AstraZeneca, and served in board positions in a number of biotech companies and the European Society of Cardiology.

Other assignments
Chairman of the Board of IRLAB Therapeutics AB (publ), Betagenon AB, Olsson Solutions AB
Board Director of Bundy Academy at Lund university and Hjärt-Lungfonden (Swedish Heart & Lung Foundation)

Experience
Jonas Brambeck (born 1958) holds a Ph.D. in Organic chemistry from the Royal Institute of Technology, Stockholm. Jonas has extensive experience in financing, divestments, and public offerings in life science companies as well as significant board experience. Currently, Jonas serves as Senior Investment Director at Industrifonden.

Other assignments
Board Director of OxThera AB and OxThera Intellectual Property AB

Experience
Thomas Bergh (born 1982) holds an M.Sc. from the Stockholm School of Economics. Thomas has served as investment manager at MedCap AB (publ). Prior to that, he spent nine years in investment banking at Morgan Stanley in Stockholm and UBS in London. Thomas currently serves as CFO of Linc AB.

Other assignments
Board Director of nWise AB, nWise Ägare AB, Animal Probiotics Sweden AB, and Oncorena Holding AB

Experience
Markus Dietrich (born 1988) holds a Ph.D. with a focus in oncology from the University of Oslo and an M.Sc. in molecular medicine from NTNU Trondheim. Markus has a background in scientific and business development in start-up companies and as business angel investor in a variety of companies across several sectors. Markus currently serves as Senior Investment Associate at Hadean Ventures, a Stockholm/Oslo-based European life science venture fund. 

Other assignments
Board Observer at Neuro Event Labs Oy (Finland) and ARTHEx Biotech S.L. (Spain)